Peginterferon alfa 2a
Common Questions and Answers about Peginterferon alfa 2a
pegasys
A total of 1050 previous nonresponders to peginterferon alfa/ribavirin were randomized to long-term therapy with low-dose peginterferon alfa-2a (90 µg/week) or no treatment. Primary outcomes assessed at 3.5 years included death, hepatic decompensation, the development of hepatocellular carcinoma, and histologic fibrosis progression in patients who were noncirrhotic at baseline.
Taken together, since the publication of the pivotal phase 3 trials for peginterferon alfa-2a and alfa-2b in combination with ribavirin, it took another 8 years to characterize the pharmacodynamic differences between the 2 drugs in detail," Zeuzem wrote.
Lamivudine for 52 weeks versus placebo increased HBeAg loss at 16 weeks off therapy. HBeAg loss at 24 weeks post treatment was greater after peginterferon alfa-2a versus lamivudine.
HBeAg seroconversion was assessed in 36 studies. Lamivudine or adefovir increased HBeAg seroconversion versus placebo. Interferon alfa-2b64,83 increased post-treatment seroconversion. Lamivudine monotherapy failed to sustain seroconversion.
I want to know if there are any clinical comparative studies on the efficacy and potency between Peg IFN Alfa 2a (pegasys) and peg IFN Alfa 2b (pegintron). I am about to begin the treatment to get rid of the virus and i am doing more readings and research into this one. I weigh 103 kg 30 yrs old. got a 10million viral load. your help is highly appreciated. Thank you.
Thirteen patients with HBeAg-negative CHB received peginterferon alfa-2a (180 microg/week) for 60 wk or peginterferon alfa-2a (180 microg/week) for 12 wk followed by 48 wk of peginterferon alfa-2a plus lamivudine.
Ocular side effects associated with oral ribavirin in combination with peginterferon alfa-2a, peginterferon alfa-2b, or interferon alfa-2b have included blurred vision (up to 6%). Corneal ulcer has been reported in less than 1% of patients treated with peginterferon alfa-2a alone or in combination with ribavirin tablets. Conjunctivitis (up to 5%) has been reported with ribavirin capsules/oral solution in combination with peginterferon alfa-2b or interferon alfa-2b.
These results are similar to those seen with the 48-week treatment regimen of VICTRELIS added to peginterferon alfa-2b and ribavirin in HCV RESPOND-2, a pivotal Phase III study. Taken together, these studies showed that VICTRELIS combined with either peginterferon alfa-2a or alfa-2b and ribavirin achieved significantly higher SVR rates in chronic HCV genotype 1 patients who failed prior therapy compared to peginterferon and ribavirin alone.
Selection of Weight-Based Peginterferon alfa-2b or Fixed-Dose Peginterferon alfa-2a
Large clinical trials suggest that in genotype 1 HCV–infected patients treated with peginterferon alfa-2a or alfa-2b plus ribavirin (at variable dosing), SVR rates range between 42% and 46%. However, differences in study design, treatment regimens, and patient populations preclude comparison of the data across these trials.
1 ratio to one of two INCIVEK combination treatment groups (with and without a Peg-IFN-alfa-2a/RBV lead-in) or a control group. The T12/PR48 group received INCIVEK and Peg-IFN-alfa-2a/RBV for 12 weeks (without a lead-in), followed by placebo and Peg-IFN-alfa-2a/RBV for 4 weeks, followed by Peg-IFN-alfa-2a/RBV for 32 weeks.
Direct hyperbilirubinemia was also more frequent with peginterferon lambda vs peginterferon alfa-2a. Indeed, 4 patients discontinued peginterferon lambda as a result of elevated bilirubin vs 0 patients receiving peginterferon alfa-2a. After discontinuing or reducing the dose of peginterferon lambda, bilirubin levels decreased rapidly.
Pegasys is a brand name for Peginterferon alfa-2a or Pegylated interferon alfa-2a which is an antiviral drug made by La Roche. It is given by injection. It is used in combination with another medication called Ribavirin (a pill), and a third medication, either Victrellis or Incivek, which are both pills, to treat Hepatitis C.
Let us know if you have further questions.
[24] Therefore, it is the recommendation of this author to reduce ribavirin stepwise by 200 mg every 2-4 weeks until adverse events either resolve or are tolerable. Peginterferon alfa-2a can be reduced from 180 to 135 µg/week and peginterferon alfa-2b from 1.5 to 1.0 µg/kg/week. Neither peginterferon alfa nor ribavirin dosing should be interrupted unless the adverse event is particularly severe and there is a concern for patient safety.
TRIPLE 1500 (1500 mg R1626 bid + peginterferon alfa-2a + ribavirin; n = 31); or standard of care (SOC) (peginterferon alfa-2a + ribavirin; n = 20). At 4 weeks HCV RNA was undetectable (<15 IU/mL) in 29%, 69%, and 74% of patients in the DUAL 1500, DUAL 3000, and TRIPLE 1500 arms, respectively, compared with 5% of patients receiving SOC, with respective mean reductions in HCV RNA from baseline to week 4 of 3.6, 4.5, 5.2, and 2.4 log(10) IU/mL.
My doc had to stop the peginterferon alfa-2a due to a lot of side effects. My Question is, now its going to be more then a month since i have not taken PEG. i have a dry Dry throat and unable to sleep properly even after taking sleeping pill and also having gray Phlegm and sometime chest congestion. My respiratory doc say that the Phlegm and chest congestion is due to PEG so i have being prescribe foracort 400 and montair lc for 15 days. My Hepatology doc ask me to do Vit D test.
Recommended
